Sign up to save your podcasts
Or
Share Johnson & Johnson Soars on Approval of Bladder Cancer Device, Solid Earnings
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Johnson & Johnson Soars on Approval of Bladder Cancer Device, Solid Earnings
# Johnson & Johnson Stock Analysis: New Cancer Treatment Approval Boosts Growth Outlook
In this insightful episode, we dive deep into Johnson & Johnson's current market position, trading at approximately $177 per share after a slight dip from $178. Despite three consecutive down days, the healthcare giant remains near its 12-month high with unusually light trading volume—just 1.2 million shares compared to the typical 9 million average.
Discover how J&J's impressive 15% three-month price climb outperforms the broader market, and learn about the game-changing FDA approval of Inlexzo, their innovative bladder cancer treatment device. We explore management's bullish forecast of $5+ billion in annual sales from this new technology, complementing their strong Q2 performance with revenues of $23.7 billion (up 6% year-over-year) and earnings of $2.77 per share that exceeded analyst expectations.
Our analysis covers the mixed but generally positive analyst sentiment, with price targets ranging from the consensus $176 to Citigroup's optimistic $200 projection, alongside the 20+ recent upward EPS revisions. We also highlight why income investors continue to value J&J's remarkable 65-year dividend growth streak and current 3% yield, while acknowledging the ongoing litigation and inflation challenges facing this healthcare stalwart.
#JohnsonAndJohnson #StockAnalysis #Inlexzo #CancerTreatment #DividendStocks #HealthcareInvesting #MedicalTechnology
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
In this insightful episode, we dive deep into Johnson & Johnson's current market position, trading at approximately $177 per share after a slight dip from $178. Despite three consecutive down days, the healthcare giant remains near its 12-month high with unusually light trading volume—just 1.2 million shares compared to the typical 9 million average.
Discover how J&J's impressive 15% three-month price climb outperforms the broader market, and learn about the game-changing FDA approval of Inlexzo, their innovative bladder cancer treatment device. We explore management's bullish forecast of $5+ billion in annual sales from this new technology, complementing their strong Q2 performance with revenues of $23.7 billion (up 6% year-over-year) and earnings of $2.77 per share that exceeded analyst expectations.
Our analysis covers the mixed but generally positive analyst sentiment, with price targets ranging from the consensus $176 to Citigroup's optimistic $200 projection, alongside the 20+ recent upward EPS revisions. We also highlight why income investors continue to value J&J's remarkable 65-year dividend growth streak and current 3% yield, while acknowledging the ongoing litigation and inflation challenges facing this healthcare stalwart.
#JohnsonAndJohnson #StockAnalysis #Inlexzo #CancerTreatment #DividendStocks #HealthcareInvesting #MedicalTechnology
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
View all episodes
By Inception Point Ai# Johnson & Johnson Stock Analysis: New Cancer Treatment Approval Boosts Growth Outlook
In this insightful episode, we dive deep into Johnson & Johnson's current market position, trading at approximately $177 per share after a slight dip from $178. Despite three consecutive down days, the healthcare giant remains near its 12-month high with unusually light trading volume—just 1.2 million shares compared to the typical 9 million average.
Discover how J&J's impressive 15% three-month price climb outperforms the broader market, and learn about the game-changing FDA approval of Inlexzo, their innovative bladder cancer treatment device. We explore management's bullish forecast of $5+ billion in annual sales from this new technology, complementing their strong Q2 performance with revenues of $23.7 billion (up 6% year-over-year) and earnings of $2.77 per share that exceeded analyst expectations.
Our analysis covers the mixed but generally positive analyst sentiment, with price targets ranging from the consensus $176 to Citigroup's optimistic $200 projection, alongside the 20+ recent upward EPS revisions. We also highlight why income investors continue to value J&J's remarkable 65-year dividend growth streak and current 3% yield, while acknowledging the ongoing litigation and inflation challenges facing this healthcare stalwart.
#JohnsonAndJohnson #StockAnalysis #Inlexzo #CancerTreatment #DividendStocks #HealthcareInvesting #MedicalTechnology
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
In this insightful episode, we dive deep into Johnson & Johnson's current market position, trading at approximately $177 per share after a slight dip from $178. Despite three consecutive down days, the healthcare giant remains near its 12-month high with unusually light trading volume—just 1.2 million shares compared to the typical 9 million average.
Discover how J&J's impressive 15% three-month price climb outperforms the broader market, and learn about the game-changing FDA approval of Inlexzo, their innovative bladder cancer treatment device. We explore management's bullish forecast of $5+ billion in annual sales from this new technology, complementing their strong Q2 performance with revenues of $23.7 billion (up 6% year-over-year) and earnings of $2.77 per share that exceeded analyst expectations.
Our analysis covers the mixed but generally positive analyst sentiment, with price targets ranging from the consensus $176 to Citigroup's optimistic $200 projection, alongside the 20+ recent upward EPS revisions. We also highlight why income investors continue to value J&J's remarkable 65-year dividend growth streak and current 3% yield, while acknowledging the ongoing litigation and inflation challenges facing this healthcare stalwart.
#JohnsonAndJohnson #StockAnalysis #Inlexzo #CancerTreatment #DividendStocks #HealthcareInvesting #MedicalTechnology
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI